Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ACRV
Upturn stock ratingUpturn stock rating

Acrivon Therapeutics, Inc. Common Stock (ACRV)

Upturn stock ratingUpturn stock rating
$1.19
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: ACRV (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

9 Analysts rated it

Moderately tracked stock, growing coverage, gaining market and investor attention.

1 Year Target Price $11.33

1 Year Target Price $11.33

Analysts Price Target For last 52 week
$11.33Target price
Low$1.05
Current$1.19
high$10.16

Analysis of Past Performance

Type Stock
Historic Profit -34.27%
Avg. Invested days 26
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 37.63M USD
Price to earnings Ratio -
1Y Target Price 11.33
Price to earnings Ratio -
1Y Target Price 11.33
Volume (30-day avg) 9
Beta 1.56
52 Weeks Range 1.05 - 10.16
Updated Date 06/29/2025
52 Weeks Range 1.05 - 10.16
Updated Date 06/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.16

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -39.24%
Return on Equity (TTM) -62.41%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -108337790
Price to Sales(TTM) -
Enterprise Value -108337790
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA -0.43
Shares Outstanding 31355400
Shares Floating 16676349
Shares Outstanding 31355400
Shares Floating 16676349
Percent Insiders 20.78
Percent Institutions 55.04

Analyst Ratings

Rating 3
Target Price 11.33
Buy 4
Strong Buy 4
Buy 4
Strong Buy 4
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Acrivon Therapeutics, Inc. Common Stock

stock logo

Company Overview

overview logo History and Background

Acrivon Therapeutics, Inc. (ACRV) is a clinical-stage biopharmaceutical company focused on developing precision medicines for cancers where conventional therapies have limited effectiveness. Founded to address unmet needs in oncology, Acrivon is pioneering a unique patient selection approach using its proprietary OncoSignature platform.

business area logo Core Business Areas

  • Drug Development: Discovery, development, and commercialization of oncology therapeutics using Acrivon's OncoSignature platform.
  • OncoSignature Platform: Proprietary platform for patient selection based on predicting drug response, aiming to improve clinical trial outcomes and personalize cancer treatment.

leadership logo Leadership and Structure

Dr. Peter Garland serves as the Chief Executive Officer. The company has a typical biotech organizational structure, with departments focused on research, clinical development, regulatory affairs, and commercialization.

Top Products and Market Share

overview logo Key Offerings

  • ACR-368: Acrivon's lead product candidate, a Chk1/2 inhibitor, is being developed for advanced solid tumors with specific genomic alterations. It's currently in clinical trials. No current market share as no product is commercialized, it's in clinical development. Competitors include companies developing similar Chk1/2 inhibitors and therapies for the target cancer types.

Market Dynamics

industry overview logo Industry Overview

The oncology market is highly competitive and rapidly evolving, with significant unmet needs and opportunities for targeted therapies and personalized medicine.

Positioning

Acrivon is positioned as a precision oncology company leveraging its OncoSignature platform to identify patients most likely to benefit from its therapies, differentiating it from traditional 'one-size-fits-all' approaches.

Total Addressable Market (TAM)

The global oncology drug market is projected to reach hundreds of billions of dollars. Acrivon's TAM depends on the specific cancers targeted by its therapies and the success of its patient selection strategy. Their TAM is based on the specific alterations they test for.

Upturn SWOT Analysis

Strengths

  • Proprietary OncoSignature platform
  • Targeted patient selection strategy
  • Experienced leadership team
  • Potential for personalized medicine in oncology

Weaknesses

  • Dependence on clinical trial success
  • High research and development costs
  • Limited number of pipeline products
  • No commercialized product yet

Opportunities

  • Expansion of OncoSignature platform to other cancers
  • Partnerships with pharmaceutical companies
  • Potential for breakthrough therapy designation
  • Acquisition of new technologies or assets

Threats

  • Clinical trial failures
  • Regulatory hurdles
  • Competition from established pharmaceutical companies
  • Changes in healthcare reimbursement policies

Competitors and Market Share

competitor logo Key Competitors

  • MRTX
  • ARRY
  • AVXL
  • GTHX

Competitive Landscape

Acrivon's competitive advantage lies in its OncoSignature platform, which aims to improve patient selection and clinical trial outcomes. It faces competition from larger pharmaceutical companies with established oncology portfolios and companies developing similar targeted therapies.

Growth Trajectory and Initiatives

Historical Growth: Acrivon's historical growth is measured by progress in its clinical trials and development of the OncoSignature platform.

Future Projections: Future growth depends on the successful completion of clinical trials and regulatory approval of its drug candidates. Analyst estimates vary based on clinical trial outcomes and market potential.

Recent Initiatives: Recent initiatives include advancing ACR-368 through clinical trials and expanding the OncoSignature platform.

Summary

Acrivon Therapeutics is a clinical-stage biopharmaceutical company with a focus on precision oncology. Its unique OncoSignature platform could differentiate it, though it's subject to clinical trial and regulatory risks. Its financial health depends on continued funding and progress in clinical trials. The company has a potential to lead to Personalized medicine for cancer patients. Investors should be mindful of risks associated with clinical-stage biotech companies.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company website
  • SEC filings
  • Analyst reports
  • ClinicalTrials.gov
  • Yahoo Finance

Disclaimers:

The information provided is for informational purposes only and should not be considered financial advice. Market share data is approximate and may vary across different sources. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Acrivon Therapeutics, Inc. Common Stock

Exchange NASDAQ
Headquaters Watertown, MA, United States
IPO Launch date 2022-11-15
Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer Dr. Peter Blume-Jensen M.D., Ph.D.
Sector Healthcare
Industry Biotechnology
Full time employees 75
Full time employees 75

Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 for the treatment of patients with endometrial and platinum-resistant ovarian cancer, and SCCs, such as SCCHN and anal cancer. The company is also developing ACR-2316, a dual WEE1 and PKMYT1 inhibitor small molecule candidate; and a preclinical stage AP3-and co-crystallography-based preclinical cell cycle program. Acrivon Therapeutics, Inc. was incorporated in 2018 and is based in Watertown, Massachusetts.